Gallium-68 PSMA

Drug Profile

Gallium-68 PSMA

Alternative Names: (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)PSMA-HBED-CC; 68Ga-DKFZ-PSMA-11; 68Ga-HBED-CC-PSMA; 68Ga-PSMA; 68Ga-PSMA HBED-CC; 68Ga-PSMA HBED-PET/CT; 68Ga-PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-PSMA-11; 68Ga-PSMA-ligand; Ga-68 labeled DKFZ-PSMA-11; Ga-68 labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; Ga-68 labeled Glu-urea-Lys(Ahx)-HBED-CC; Ga-68 labeled PSMA-11 PET; Ga-68-PSMA-11; Gallium-68 labeled PSMA-11; ProstaMedix; PSMA-HBED-CC GA-68

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator RadioMedix
  • Developer Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori; Medical University of Vienna; Princess Alexandra Hospital; Sir Charles Gairdner Hospital; University Medical Center Groningen; University of California at San Francisco
  • Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Renal cell carcinoma

Most Recent Events

  • 02 Mar 2017 Sir Mortimer B. Davis Jewish General Hospital plans a phase II trial for Prostate cancer in Canada (NCT03062254)
  • 31 Jan 2017 Phase-III clinical trials in Prostate cancer (Diagnosis, In adults, In the elderly) in Netherlands (IV) (EudraCT2016-002485-31)
  • 04 Jan 2017 Prostate Cancer Foundation of Australia and Peter MacCallum Cancer Centre plan the ProPSMA clinical trial for Prostate cancer (Diagnosis) in Australia (ACTRN12617000005358p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top